Paul Buensuceso, MD

Gilead Sciences, Inc.

Poster(s):

• P4566 - Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 96 Interim Analysis of a Phase 3 Randomized Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET